At 9:30 am on February 4, 2018, Nanjing Biomedical Valley and Shanghai Longyao Bio held the "Longyao Biological Cell Therapy Project and Big Health Industry Fund Signing Ceremony" in the multi-functional conference hall of Nanjing Biomedical Valley Enterprise Service Center.
Member of the Standing Committee of Nanjing Municipal Party Committee and leaders of Jiangbei New District, the New District Science and Technology Innovation Bureau, the Economic Development Bureau, the Finance Bureau, the Environmental Protection and Water Affairs Bureau, the Market Supervision Bureau, and the Administrative Examination and Approval Bureau. , Jiangbei New District Industrial Investment Group, principals of Nanjing High-tech Venture Capital Co., Ltd., representatives of senior executives of Shanghai Longyao Bio, and the scientific research team of Shanghai Jiaotong University attended the signing ceremony.
Nanjing Jiangbei New Area is approved by the State Council and is the only state-level new area in Jiangsu Province. Provincial economic and social management authority. The future industrial development orientation of the new area is: "4+2" modern industrial system, focusing on the development of four major industries: intelligent manufacturing, life and health, new materials, and high-end transportation equipment.
In the field of biomedicine, relying on Nanjing Biomedical Valley, it focuses on gathering enterprises in the fields of biopharmaceuticals and medical devices to build a hundred billion-level advanced biomedical industry cluster.
Shanghai Longyao Bio has settled in Nanjing Pharmaceutical Bio Valley, Jiangbei New District, which has greatly promoted the industrial transformation of scientific research achievements in the field of biological cells, and also enhanced the competitiveness and height of the park. As a cutting-edge medical technology research and development company invested by Beike Biological Group, Shanghai Longyao Bio has been committed to technology research and development and product transformation in the field of tumor immune cell therapy for many years. It has carried out close cooperation with top international expert teams such as Southwest Medical Center, Shanghai Jiaotong University, Zhengzhou University, Xuzhou Medical University, etc., and has strong strength and profound foundation in the research and development and transformation of CAR-T products, DC1s-CTL products and other products . At present, Longyao Bio has completed a number of innovative CAR-T core technology research and development, translation and clinical work. The innovatively designed CAR-T production robot project has the characteristics of modularized process flow, streamlined cell preparation, clean internal environment and closed production process, which is conducive to product production and quality control in the field of cell therapy, and improves the It improves the uniformity and quality of products and improves the overall level of manufacturing in the field of cell therapy.
The project of Shanghai Longyao Bio in Nanjing Biomedical Valley is as follows:
1. R&D and industrialization of CAR-T in leukemia and solid tumor treatment products. Longyao Bio has established a fully automated production process system for CAR-T cell preparation and virus preparation in Biomedical Valley, completed the application and registration of CAR-T tumor therapy products based on robot preparation, and realized the standardization and standardization of CAR-T cell therapy product production. It has become a national promotion and demonstration base for the clinical application of automated CAR-T cell therapy.
2. Application and industrialization of tumor-targeted DC1-CTL immune cell technology products. Longyao Biotech completed the declaration of DC1-CTL kits targeting 14 common tumors in Biomedical Valley, and established a national production base for DC1-CTL kits to supply the global market.
3. Establishment of tissue bank and biological sample bank. Longyao Bio has set up an immune cell bank in Biomedical Valley (stores adult immune cells and customized immune cells and antigen peptide banks (antigen screening for common high-incidence tumors, antigen peptide bank).
Signing ceremony site
Chen Chanmei, Deputy Director of Nanjing Jiangbei District Management Committee, presided over the signing ceremony
Nanjing Jiangbei New Area participating bureau committees
Luo Qun, member of the Standing Committee of the CPC Nanjing Municipal Committee
Highly appraised Longyao Bio's breakthroughs in scientific research and transformation in the field of biological cells
Ye Shengqin, President of Beike Biology and Chairman of Shanghai Longyao Biology
A comprehensive introduction to the settlement project
Signing Ceremony of Longyao Biological Project Settlement
Signing Ceremony of Longyao Biological Project Settlement
Aerial view of the master plan of Jiangbei New District in Nanjing
Nanjing Biomedical Valley Planning Map